Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Two-year, Post-marketing Observational Study to Follow-up Patients With End Stage Renal Disease Undergoing Haemodialysis, Receiving Zemplar for Prevention and Treatment of Secondary Hyperparathyroidism

NCT01081665 is registered in ClinicalTrials.gov with Abbott as lead sponsor.

NCT NCT01081665
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01081665 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Two-year, Post-marketing Observational Study to Follow-up Patients With End Stage Renal Disease Undergoing Haemodialysis, Receiving Zemplar for Prevention and Treatment of Secondary Hyperparathyroidism
Lead sponsor
Abbott
Phase
Observational
Overall status
Completed
Start date
December 31, 2006
Completion date
February 28, 2011
Enrollment
237 (actual)
Sites
19

Conditions

As the registry lists them; a condition with its own page is linked.

chronic kidney failure, secondary hyperparathyroidism